Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolyPidPYPD +4.26%32 3-Year Book Growth Rate is -59.10% as of Jun. 2026. GuruFocus rates PYPD with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,121 Biotechnology companies, PolyPid ranks worse than 91.26% on this metric.
During the past 12 months, PolyPid's average Book Value per Share Growth Rate was -20.00% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -59.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of PolyPid was -27.30% per year. The lowest was -140.50% per year. And the median was -67.75% per year.
PolyPid (NAS:PYPD) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
PolyPid 3-Year Book Growth Rate Related Terms
PYPD vs PLYX, GUTS, YARW: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, PolyPid's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPid 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PolyPid's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where PolyPid's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -59.10% mean?
PolyPid (PYPD) has a 3-Year Book Growth Rate of -59.10% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for PolyPid and its competitors. According to the industry distribution chart, PolyPid ranks #1023 out of 1121 companies in the Biotechnology industry, placing it in the top 91.3%.
Is PolyPid's 3-Year Book Growth Rate too high?
PolyPid's current 3-Year Book Growth Rate is -59.10%. Based on the distribution chart, PolyPid ranks #1023 out of 1121 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PolyPid has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PolyPid's 3-Year Book Growth Rate compare to PLYX and GUTS?
According to the Biotechnology industry distribution chart, PolyPid ranks #1023 out of 1121 companies for 3-Year Book Growth Rate. This places PolyPid in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for PolyPid and its competitors. PolyPid's current 3-Year Book Growth Rate is -59.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPid stock overvalued right now?
PolyPid (PYPD) has a current 3-Year Book Growth Rate of -59.10%. The current 3-Year Book Growth Rate is -59.10%. PolyPid's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For PolyPid (PYPD), the current 3-Year Book Growth Rate is -59.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PolyPid Ltd is an Israeli clinical-stage biopharmaceutical company that develops products based on its proprietary PLEX (Polymer-Lipid Encapsulation MatriX) drug delivery technology. PLEX encapsulates drugs and releases them locally over extended periods at predetermined rates. The company's lead product candidate, D-PLEX100, is designed to deliver doxycycline directly into surgical sites to prevent surgical site infections in soft tissue and has been studied in abdominal and cardiac surgery. Another candidate, OncoPLEX, is being explored as an intratumoral therapy for solid tumors. PolyPid operates as a research and development company, with no marketed products, and its revenue model depends on future regulatory approvals, commercialization partnerships, and licensing arrangements. The company is headquartered in Petah Tikva, Israel, and its shares trade on the Nasdaq Capital Market.
32GF Score
Get the complete analysis for PYPD
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PYPD has been successfully added to your 
